The Latest News in the Peptide World

As we close out 2025, it is obvious that the peptide space is moving at an incredible rate. From massive infrastructure investments to breakthroughs in oral delivery and regenerative medicine, recent advancements are highlighting the versatility of peptides in addressing everything from rare diseases to common metabolic conditions.

Check out our latest news roundup below.

Bachem has announced that Anne-Kathrin Stoller will become the new CEO of the company. Stoller’s appointment comes at a critical time as the company continues to scale its global operations to meet rising market demand.

Bachem also continues to progress with its expansion initiative in Bubendorf and the physical expansion of its site in Vista, California. The expansion is part of a broader strategy to increase global manufacturing capacity for peptide-based active pharmaceutical ingredients.

Lifecore Biomedical and PolyPeptide Group have announced a strategic collaboration intended to offer an end-to-end peptide manufacturing solution specifically for the U.S. market. This partnership aims to streamline the development process from initial synthesis through to fill-finish.

Cambrex has unveiled a $120 million investment to expand its API manufacturing capabilities, a move designed to strengthen the U.S. drug supply chain and provide increased capacity for complex synthetic molecules, including peptides.

SK Pharmteco is boosting its domestic peptide scale-up capabilities with a new investment in its California facility. The expansion focuses on supporting the growing demand for large-scale peptide production and advanced chemical modalities.

In one of the industry's largest infrastructure moves, Eli Lilly is building a $6 billion facility in Huntsville, Alabama. This site will be dedicated to manufacturing active pharmaceutical ingredients for its metabolic and peptide-based therapies.

Syngene International has invested in a dedicated peptide laboratory featuring advanced automation. This investment is designed to accelerate development timelines and improve the efficiency of complex peptide synthesis on a global scale.

Barinthus Bio has provided an update on its Phase 1 AVALON clinical trial of VTP-1000, a peptide-based immunotherapy for the treatment of Celiac disease. The study is evaluating the safety and immune response of this novel approach to treating autoimmune sensitivity.

Treos Bio announced the publication of Phase 1b clinical trial results for PolyPePi1018 in combination with TAS-102. Designed to be an "off-the-shelf" peptide immunotherapy, PolyPePi1018 is being developed for patients with refractory microsatellite stable (MSS) metastatic colorectal cancer.

CDMO giant Catalent and Lisata Therapeutics have entered into a collaboration focused on leveraging Lisata’s tumor-targeting peptide technology to enhance the delivery of Catalent's Antibody-Drug Conjugates (ADCs).

Subsequently, Lisata Therapeutics highlighted positive preclinical data for certepetide, their cyclic peptide that enhances tumor penetration. When incorporated directly into Catalent’s ADCs , certepetide significantly improved their distribution and efficacy in treating solid tumors.

Dayra Therapeutics has launched with a foundational partnership with Biogen. Dayra will focus on developing oral macrocyclic peptides, a modality that combines the potency of biologics with the convenience of oral administration.

Ascletis has selected its lead oral small molecule GLP-1 receptor agonist candidate, hoping to meet the growing demand for convenient, non-injectable treatments for obesity and type 2 diabetes.

PepGen has been issued a U.S. patent for its proprietary PGN-EDODM1 molecule. The technology uses specialized peptides to enhance the delivery of oligonucleotides, potentially improving the treatment of rare neuromuscular diseases.

LIR Life Sciences has completed the design of a comparative animal study investigating cell-penetrating peptide-mediated delivery. This technology aims to enable more effective delivery of GLP/GIP-based therapies for obesity.

ITM Radiopharma received FDA Fast Track Designation for ITM-94, a peptide-based diagnostic agent developed for the detection and diagnosis of clear cell renal cell carcinoma (ccRCC).

Italian biotech Nanophoria has secured nearly $100M in Series A funding. Nanophoria is developing a non-viral, peptide-based delivery platform specifically designed to treat chronic heart failure.

NervGen Pharma reported expanded data from its Phase 1b/2a study showing "unprecedented" durable improvements in motor function and quality of life for patients with chronic spinal cord injuries using its lead peptide candidate.

OKYO Pharma announced positive data from its Phase 2 study for neuropathic corneal pain. The study demonstrated favorable corneal nerve outcomes, highlighting the potential for peptide therapeutics in specialized ophthalmic care.

Recent reports highlight progress in identifying peptides that regulate stress responses in the brain. These "stress peptides" are becoming a key area of focus for developing next-generation psychiatric and neurological treatments.

An Agilent Research Catalyst (ARC) Award was presented to UC Davis Professor Marie Heffern for breakthroughs in characterization of peptide therapeutics. Professor Heffern’s research focuses on how metal interactions influence peptide drug stability and function, providing critical insights for future drug design.